GlassScriptPhysician profile
Kristin M Daly
NPI 1275951147
$11,170.60
in general payments reported to CMS, 2019-2025
43 companies · $2,669 in 2025
The $2,669 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $758 · 2022: $1,948 · 2023: $3,515 · 2024: $2,281 · 2025: $2,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,861 · Consulting Fee: $1,311 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,860.98 |
| Consulting Fee | $1,311.26 |
| Education | $293.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $1,465.28 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,161.94 | 2023-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $1,069.74 | 2021-2025 | Calquence, Enhertu, Fasenra |
| Gilead Sciences, INC. | $944.37 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $641.63 | 2021-2024 | |
| Amgen INC. | $635.26 | 2022-2025 | Vectibix |
| Incyte Corporation | $369.76 | 2021-2025 | Pemazyre, Zynyz |
| Jazz Pharmaceuticals INC. | $314.75 | 2022-2025 | |
| Abbvie INC. | $257.25 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $250.44 | 2023 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $249.52 | 2022-2025 | Lynozyfic |
| Kyowa Kirin, INC. | $243.64 | 2023-2024 | Nourianz, Crysvita |
| Genentech USA, INC. | $241.99 | 2021-2022 | |
| Seagen INC. | $211.42 | 2022-2023 | Tukysa |
| Puma Biotechnology, INC. | $181.29 | 2021-2023 | Nerlynx |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.